The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for providers and patients. An urgent need for rapid access to COVID-19 testing, treatments, and vaccines has ushered in federal and health plan policies to eliminate barriers to care. Federal COVID-19 relief legislation eliminated co-payments for many of those services and paused prior authorization requirements for testing.1
Prior authorization policies may pose a barrier to timely and necessary medical services, which can delay acute and postacute care. When quick intervention is necessary, delays can reduce quality of care and increase disease burden. For hospital patients, delays in prior authorization result in longer stays that drive up costs. Procedures for obtaining prior authorization are often burdensome and vary among payers. Appealing prior authorization decisions is frequently onerous and disheartening for patients as well as their providers—indeed, few Medicare beneficiaries and providers pursue such appeals.2
In September 2018, the HHS Office of Inspector General (OIG) reported on Medicare Advantage (MA) plan prior authorization policies and appeals.2 The OIG found high rates of overturned prior authorization and payment denials and identified problems related to denials of care and payment. Among other recommendations, the OIG urged HHS to address inappropriate denials and insufficient denial communications.
Legislation introduced during the last Congress (Improving Seniors’ Timely Access to Care Act, HR 3107) would take important steps toward improving prior authorization under MA. It had broad patient and provider support, and we encourage the managed care community to implement these improvements.
Further, as managed care plans consider their postpandemic policies, they should examine the impact of prior authorization requirements, including on access to postacute care. Actions to reduce the burden of prior authorization, interfere less with patient care, save administrative costs, and better target overuse, waste, and abuse include:
These key improvements will promote transparency, efficiency, and timely decision-making, which ultimately will lead to better patient care.
REFERENCES
1. Families First Coronavirus Response Act, Pub L No. 116-127, 134 Stat 177 (2020).
2. Medicare Advantage appeal outcomes and audit findings raise concerns about service and payment denials. HHS Office of Inspector General. September 25, 2018. Accessed March 29, 2021. https://oig.hhs.gov/oei/reports/oei-09-16-00410.asp
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More